Amy E Sobota1,2, Nishita Shah3, Jennifer W Mack4,5. 1. Boston University School of Medicine, Boston, Massachusetts. 2. Department of Pediatrics, Boston Medical Center, Boston, Massachusetts. 3. Boston University School of Public Health, Boston, Massachusetts. 4. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts. 5. Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Transition from pediatric to adult care is a vulnerable time for young adults with sickle cell disease (SCD); however, improvements in transition are limited by a lack of quality indicators. The purpose of this study was to establish quality indicators for transition in SCD and to determine the optimal timing between the final pediatric visit and the first adult provider visit. PROCEDURE: We conducted a modified Delphi survey to reach a consensus on which quality indicators are most important for a successful transition. Our expert panel consisted of members of the Sickle Cell Adult Provider Network. In the first round, the participants ranked a list of quality indicators by importance. In the second round, the participants chose their "top 5" quality indicators in terms of importance and also ranked them on feasibility. RESULTS: The response rates for the two rounds were 68 and 96%, respectively. Nine quality indicators were chosen as "top 5" by a majority of respondents, including communication between pediatric and adult providers, timing of first adult visit, patient self-efficacy, quality of life, and trust with their adult provider. Based on the comments from round 1, respondents were also asked for the optimal timing between leaving pediatric care and entering adult care. Most recommended a first adult visit within 2 months of the final pediatric visit. CONCLUSIONS: By using these quality indicators chosen by the majority of respondents, we can better develop and evaluate transition programs for young adults with SCD and improve health outcomes for these vulnerable patients.
BACKGROUND: Transition from pediatric to adult care is a vulnerable time for young adults with sickle cell disease (SCD); however, improvements in transition are limited by a lack of quality indicators. The purpose of this study was to establish quality indicators for transition in SCD and to determine the optimal timing between the final pediatric visit and the first adult provider visit. PROCEDURE: We conducted a modified Delphi survey to reach a consensus on which quality indicators are most important for a successful transition. Our expert panel consisted of members of the Sickle Cell Adult Provider Network. In the first round, the participants ranked a list of quality indicators by importance. In the second round, the participants chose their "top 5" quality indicators in terms of importance and also ranked them on feasibility. RESULTS: The response rates for the two rounds were 68 and 96%, respectively. Nine quality indicators were chosen as "top 5" by a majority of respondents, including communication between pediatric and adult providers, timing of first adult visit, patient self-efficacy, quality of life, and trust with their adult provider. Based on the comments from round 1, respondents were also asked for the optimal timing between leaving pediatric care and entering adult care. Most recommended a first adult visit within 2 months of the final pediatric visit. CONCLUSIONS: By using these quality indicators chosen by the majority of respondents, we can better develop and evaluate transition programs for young adults with SCD and improve health outcomes for these vulnerable patients.
Authors: Adrienne S Viola; Richard Drachtman; Amanda Kaveney; Ashwin Sridharan; Beth Savage; Cristine D Delnevo; Elliot J Coups; Jerlym S Porter; Katie A Devine Journal: J Pediatr Psychol Date: 2021-07-20
Authors: Anjelica C Saulsberry-Abate; Marita Partanen; Jerlym S Porter; Pradeep S B Podila; Jason R Hodges; Allison A King; Winfred C Wang; Jane E Schreiber; Xiwen Zhao; Guolian Kang; Lisa M Jacola; Jane S Hankins Journal: Br J Haematol Date: 2021-02-11 Impact factor: 6.998
Authors: M Eva Mingot-Castellano; M Teresa Álvarez Román; Luis Fernando Fernández Fuertes; Tomás José González-López; José María Guinea de Castro; Isidro Jarque; M Fernanda López-Fernández; Maria Luisa Lozano; Blanca Sánchez González; David Valcárcel Ferreiras; José Ramón González Porras Journal: Adv Hematol Date: 2019-08-22
Authors: Sophie Lanzkron; Gregory S Sawicki; Kathryn L Hassell; Michael W Konstan; Robert I Liem; Susanna A McColley Journal: J Clin Transl Sci Date: 2018-10
Authors: Katherine Bailey; Stephanie Lee; Thomas de Los Reyes; Lisha Lo; Jan Willem Gorter; Alene Toulany Journal: BMJ Open Date: 2021-11-01 Impact factor: 2.692